Skip to content

Compounds · Brain & nerves · Stimulation of natural growth hormone production

Sermorelin (Geref)

Full protocol

Geref, GRF 1-29, GHRH (1-29), Sermorelin acetate

A 29-amino-acid GHRH analogue, the shortest fully active GHRH fragment, approved by the FDA in the 1990s for pediatric growth hormone deficiency and diagnostics, then discontinued commercially in 2008 for business reasons, not safety. It prompts natural pulsatile GH release and remains available through compounding pharmacies, often for off-label age-management use.

0.2–0.3 mg nightly

Research score 78/100. Reference only, not a prescription.

  • Growth Hormone Release
  • Sleep Improvement
  • Cognitive Enhancement
  • Anti-aging
  • Recovery Enhancement
  • Hormone Regulation
US status
Prescription Only (via compounding pharmacy)
Approval
FDA approved (1997), but commercially discontinued in 2008. Available via compounding pharmacies.
Evidence
Extensive Human Studies prior to 2008. A 2021 study showed benefits in an animal model of heart failure.
Research score
78 / 100
Indication
Growth Hormone Deficiency
Origin
USA
Source category
Brain & Nervous System
Status group
Approved / prescription

Mechanism

Binds GHRH receptors on pituitary somatotrophs, raising cAMP via adenylate cyclase to trigger PKA activity, calcium influx, and GH vesicle release; it also upregulates GHRH receptor expression, preserving natural GH pulsing patterns.

Safety file

Good tolerability profile.

  • Injection site reactions
  • Headache
  • Dizziness
  • Flushing
  • Transient hypoglycemia
  • Restlessness

Reconstitution

Concentration by vial size and water volume
Vial2 mL water3 mL water
10 mg5 mg/mL3.33 mg/mL

Sermorelin can leave a small welt at the injection site. Reconstituting with bac water that contains 0.9% sodium chloride (rather than plain) reduces that reaction for some people. Either works.

  1. Use bacteriostatic water as the diluent.
  2. Add the water slowly, letting it run down the inside wall of the vial rather than onto the powder.
  3. Swirl gently to mix, then leave it to dissolve. Do not shake.
  4. Give it a few minutes. The finished solution should be clear and colourless.

Full mixing method

Protocol

Route: Subcutaneous

Standard protocol (subcutaneous)

  • 0.2 mg to 0.3 mg once nightly before bed, on an empty stomach, to ride the natural deep-sleep GH pulse
  • Daily dosing, since the half-life is very short (about 10 minutes)

Dosing detail

  • Common dose is 0.2 mg to 0.3 mg, once nightly before bed.
  • Inject on an empty stomach; food blunts the GH pulse.
  • Short half-life means daily dosing is needed for steady effect.
  • A brief flush after injecting is common and passes quickly.

Duration

  • Run 8 to 12 weeks, often 5 days on and 2 off, then take a break. Sleep improvements often show up first, within a couple of weeks.

Notes

  • A GHRH analogue that nudges your own GH output rather than replacing it.
  • A brief flush after injecting is common and passes quickly.
  • Inject subcutaneously and rotate sites.

Storage and handling

  • Keep the powdered (lyophilized) vial in a cool, dark place. Refrigerate it for longer-term storage before mixing.
  • Once reconstituted and refrigerated at 2–8 °C away from light, use the vial within 28 days.
  • Do not freeze a reconstituted vial, and keep it away from heat and sunlight.
  • If the solution turns cloudy, develops floating particles, or shows any other sign of degradation, stop using that vial.

Storage rules and when to discard